(UTHR) United Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91307C1027

UTHR: Pulmonary Arterial Hypertension, Cancer, Gene Therapy Products

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company with a singular focus on addressing the unmet medical needs of patients with chronic and life-threatening diseases. Their mission is to improve the quality of life for these patients through innovative therapies. The companys expertise lies in pulmonary arterial hypertension (PAH), a rare and debilitating disease, where they have established a robust portfolio of treatments.

Their product portfolio includes Tyvaso DPI, an inhaled dry powder formulation, and Tyvaso, an inhaled solution, both designed for PAH treatment. Remodulin (treprostinil) injection is another key offering, aimed at reducing exercise-related symptoms in PAH patients. Orenitram, a tablet form of treprostinil, delays disease progression and enhances exercise capacity. Adcirca, an oral PDE-5 inhibitor, further complements their PAH treatments by improving exercise ability.

Beyond PAH, United Therapeutics markets Unituxin (dinutuximab), a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump system for Remodulin delivery. Their R&D pipeline is promising, with RemoPro and Ralinepag for PAH, Aurora-GT gene therapy to regenerate lung blood vessels, and Nebulized Tyvaso for idiopathic pulmonary fibrosis. They are also pioneering xenografts, developmental organ products.

Strategic collaborations enhance their capabilities: with DEKA for a subcutaneous treprostinil delivery system, MannKind for a treprostinil inhalation powder, and Arena Pharmaceuticals for Ralinepag development. These partnerships underscore their commitment to innovation and patient care.

Founded in 1996 and headquartered in Silver Spring, Maryland, United Therapeutics is a leader in its niche. With a market cap of $15.68B and P/E ratio of 15.43, they show stability and potential growth, making them a notable player in biotech for investors seeking exposure to innovative therapies.

Additional Sources for UTHR Stock

UTHR Stock Overview

Market Cap in USD 15,678m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 1999-06-17

UTHR Stock Ratings

Growth 5y 96.4%
Fundamental 74.3%
Dividend 0.0%
Rel. Strength Industry 74.6
Analysts 3.94/5
Fair Price Momentum 417.61 USD
Fair Price DCF 170.29 USD

UTHR Dividends

No Dividends Paid

UTHR Growth Ratios

Growth Correlation 3m -36.7%
Growth Correlation 12m 92.2%
Growth Correlation 5y 91.9%
CAGR 5y 28.10%
CAGR/Mean DD 5y 2.75
Sharpe Ratio 12m 1.89
Alpha 55.08
Beta 0.71
Volatility 30.83%
Current Volume 209.4k
Average Volume 20d 356.7k
What is the price of UTHR stocks?
As of February 18, 2025, the stock is trading at USD 370.58 with a total of 209,350 shares traded.
Over the past week, the price has changed by +7.22%, over one month by +3.25%, over three months by +3.17% and over the past year by +73.04%.
Is United Therapeutics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, United Therapeutics (NASDAQ:UTHR) is currently (February 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 74.32 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of UTHR as of February 2025 is 417.61. This means that UTHR is currently undervalued and has a potential upside of +12.69% (Margin of Safety).
Is UTHR a buy, sell or hold?
United Therapeutics has received a consensus analysts rating of 3.94. Therefor, it is recommend to buy UTHR.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0
What are the forecast for UTHR stock price target?
According to ValueRays Forecast Model, UTHR United Therapeutics will be worth about 496.8 in February 2026. The stock is currently trading at 370.58. This means that the stock has a potential upside of +34.05%.
Issuer Forecast Upside
Wallstreet Target Price 402.2 8.5%
Analysts Target Price 398 7.4%
ValueRay Target Price 496.8 34%